Table 4:
Comparison between primary open angle glaucoma patients with and without autoimmune diseases
| Demographic and Ophthalmic Information | POAG with autoimmune disease (n = 30) | POAG without autoimmune disease (n = 142) | p-value |
|---|---|---|---|
| Age (years) | 72.3±9.1 | 73.1±9.0 | 0.65 |
| Gender (% male) | 30.0 | 48.6 | 0.06 |
| Race (% White) | 73.3 | 47.9 | 0.01 |
| BMI (kg/m2) | 27.0±5.5 | 27.3±4.8 | 0.81 |
| Type 2 diabetes (%) | 26.7 | 32.6 | 0.52 |
| Any history of steroid usea (%) | 26.7 | 11.9 | 0.04 |
| BCVA (LogMAR) | 0.3±0.3 | 0.3±0.5 | 0.77 |
| HVF MD (decibels)b | −11.0±7.7 | −13.5±8.6 | 0.23 |
| IOP (mm Hg) | 15.0±3.8 | 16.0±6.7 | 0.42 |
| IOP max (mm Hg) | 27.1±7.1 | 26.1±8.8 | 0.58 |
| Cup to disc ratio | 0.8±0.1 | 0.8±0.1 | 0.94 |
| Average RNFL thickness (μm)c | 67.8±6.6 | 63.9±10.4 | 0.13 |
All values are expressed as mean ± standard deviation unless otherwise specified. Data from the more affected eye are presented.
Any history of systemic steroid use for > 4 weeks in duration, inhaled steroid use for > 3 months in duration and topical steroid use for > 4 weeks in duration.
Available for 66.7% patients with autoimmune disease and 65.5% of patients without autoimmune disease.
Available for 60% patients with autoimmune disease and 62% of patients without autoimmune disease.
Abbreviations: BCVA, best corrected visual acuity; BMI, body mass index; CDR, cup to disc; HVF MD, Humphrey visual field mean deviation; IOP, intraocular pressure; LogMAR, logarithm of the minimum angle of resolution; POAG, primary open angle glaucoma; RNFL, retinal nerve fiber layer thickness.